- Home
- RY vs GILD Comparison
RY vs GILD Comparison
Compare RY & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RY | GILD |
|---|---|---|
| Founded | 1864 | 1987 |
| Country | Canada | United States |
| Employees | 100000 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.4B | 187.5B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | RY | GILD |
|---|---|---|
| Price | $163.62 | $145.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 18 |
| Target Price | ★ $162.00 | $143.50 |
| AVG Volume (30 Days) | 1.0M | ★ 6.3M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 2.75% | 2.28% |
| EPS Growth | N/A | ★ 1684.21 |
| EPS | N/A | ★ 6.78 |
| Revenue | N/A | ★ $24,689,000,000.00 |
| Revenue This Year | $17.12 | $4.68 |
| Revenue Next Year | $4.56 | $6.10 |
| P/E Ratio | ★ $17.01 | $21.23 |
| Revenue Growth | N/A | ★ 9.98 |
| 52 Week Low | $106.10 | $95.30 |
| 52 Week High | $176.19 | $157.29 |
Technical Indicators
Market Signals| Indicator | RY | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 38.34 | 50.89 |
| Support Level | $143.26 | $143.09 |
| Resistance Level | $175.21 | $157.29 |
| Average True Range (ATR) | 3.10 | 3.27 |
| MACD | -0.95 | -1.43 |
| Stochastic Oscillator | 18.34 | 24.02 |
Price Performance
Historical ComparisonAbout RY Royal Bank Of Canada
Royal Bank of Canada is one of the two largest banks in Canada, with around CAD 2.3 trillion in assets at the end of fiscal 2025. It is a diversified financial services company, offering personal and commercial banking, wealth management, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada and has dominant market shares. RBC also has wealth and capital market businesses in the US, UK, and other countries. RBC is a top 15 investment bank globally.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).